If a physician banks or processes a patient’s adipose tissue through a third-party lab, the quality of that tissue is governed by a federal standard called Current Good Tissue Practice. CGTP lives in Subpart D of 21 CFR Part 1271 and applies to every registered HCT/P establishment, including those making 361 products that need no pre-market approval. The physician who uses the tissue is not insulated from that lab’s failures. What follows is what CGTP requires and a concrete way for a physician to evaluate whether a lab partner actually meets it.
TLDR: Current Good Tissue Practice, set out in Subpart D of 21 CFR Part 1271 (Sections 1271.150 through 1271.290 and beyond), is the FDA quality standard for HCT/P manufacturers, covering personnel, procedures, facilities, environmental monitoring, equipment, supplies, processing, labeling, storage, records, and deviation reporting. Records must be retained at least 10 years. CGTP applies to 361 establishments too. A physician using a lab partner shares exposure if that partner fails CGTP and a patient is harmed, so reviewing the partner’s compliance is part of due diligence, not optional. Banking adipose tissue does not enroll a patient in therapy and does not guarantee any future eligibility, access, or benefit.
Important Disclaimer: Save My Fat does not provide FDA-approved treatments or cures for any disease. Banking adipose tissue today does not guarantee eligibility, access, or clinical benefit from any future therapy, clinical trial, or medical program. No adipose-derived stem cell product currently holds FDA approval for the conditions discussed in this article. All content is for educational purposes only and does not constitute medical advice. Patients must consult their own licensed healthcare professionals regarding all medical decisions.
A lab partner’s compliance is not an abstraction a physician can delegate and forget. It is a question with a paper trail, and the physician who knows which documents to ask for is in a very different position from the one who takes a sales deck at face value. The sections below are organized so that a physician or practice administrator can turn each requirement into a question for a prospective lab.
What CGTP Is and Where It Comes From
Current Good Tissue Practice is the FDA’s quality standard for establishments that manufacture human cells, tissues, and cellular and tissue-based products. Its requirements are codified in Subpart D of 21 CFR Part 1271, running from Section 1271.150 onward. The goal is to prevent the introduction, transmission, or spread of communicable disease and to ensure tissue quality. Critically, CGTP applies to all registered HCT/P establishments, including those that manufacture 361 products requiring no approval, which is the point physicians most often miss: the absence of a pre-market approval step does not mean the absence of a federal quality standard.
Why the Physician Is Not Off the Hook
A physician who contracts out processing and storage does not contract out responsibility. Under 21 CFR Part 1271, the physician who uses the HCT/P sits in the distribution chain. Florida’s SB 1768 makes the point explicit by requiring accreditation and a post-thaw viability report before use. The practical reality is blunt: if a lab partner violates CGTP and a patient is harmed, the physician who used that tissue can face regulatory, civil, and in egregious cases criminal exposure. Choosing a lab partner is therefore a clinical risk decision, not a procurement formality.
The Core CGTP Requirements
Each requirement below maps to a section of Subpart D. The plain-language gloss is what the requirement means for a physician sizing up a lab.
Personnel (1271.170): sufficient staff with documented education, training, and experience for their functions. Procedures (1271.180): established, documented standard operating procedures for every manufacturing step. Facilities (1271.190): designed and maintained to prevent contamination and mix-ups. Environmental control and monitoring (1271.195): air quality, temperature, and other conditions monitored and documented. Equipment (1271.200): maintained, calibrated, and qualified. Supplies and reagents (1271.210): only acceptable materials, with documented supplier qualification. Recovery (1271.215): documented, controlled procedures for recovering tissue. Processing and process controls (1271.220): all steps documented, with validation where applicable. Labeling controls (1271.250 through 1271.290): every HCT/P labeled with required information. Storage (1271.260): controlled, documented storage conditions and expiration. Records (1271.270): a records management system, with retention of at least 10 years. Tracking and adverse-reaction and deviation reporting (1271.290 and 1271.350): events that may affect safety investigated and reported.
A note on record retention, because it is concrete and verifiable: Section 1271.270 requires that records be kept at least 10 years after their creation, and records pertaining to a particular HCT/P at least 10 years after its administration, distribution, disposition, or expiration, whichever is latest. If a lab cannot commit in writing to that retention period, that is a finding.
CGTP Requirements Summary Table
| Requirement | CFR section | What to ask your lab |
|---|---|---|
| Personnel qualifications | 1271.170 | “Do you have documented training records for all staff who process HCT/Ps?” |
| SOPs | 1271.180 | “Can you provide the SOPs for the specific steps used on our tissue?” |
| Facility design | 1271.190 | “How is the processing environment designed and controlled to prevent contamination?” |
| Environmental monitoring | 1271.195 | “What is your environmental monitoring program and how often are results reviewed?” |
| Equipment | 1271.200 | “What is your equipment calibration and maintenance schedule?” |
| Supplies and reagents | 1271.210 | “How do you qualify and re-qualify reagent suppliers?” |
| Process controls | 1271.220 | “What process validation data do you have for your cryopreservation protocol?” |
| Labeling | 1271.250-290 | “Does each unit include all required labeling, including donor eligibility?” |
| Records | 1271.270 | “Do you retain processing records at least 10 years, and can we access them?” |
| Deviation reporting | 1271.350 | “What is your process for investigating and reporting deviations?” |
Red Flags in Lab Partner Due Diligence
Specific warning signs when evaluating a prospective lab: it cannot produce current FDA registration documentation; it cannot describe how its processing environment is controlled; it has no documented SOPs, or calls them “proprietary” and refuses any review; it has never been FDA-inspected or has unresolved Form 483 observations; it cannot produce process validation data for its cryopreservation protocol; its deviation process is informal or undocumented; and it cannot provide a post-thaw viability summary from prior batches. Any one of these warrants slowing down. Two or more is a reason to walk. The patterns that separate legitimate labs from problem operators overlap heavily with the warning signs covered in the guide on spotting fake stem cell clinics.
A clarifying point on the Florida question specifically: SB 1768 requires FDA registration, accreditation, and a post-thaw viability report. Facility-environment controls such as filtration are governed by CGTP under Section 1271.190, not by a separate HEPA mandate in the enrolled Florida statute. Verify environmental expectations against CGTP and the current statute rather than a superseded draft of the bill.
Lab Partner Evaluation Checklist
- FDA registration confirmed and current in HCTERS.
- Accreditation confirmed for Florida providers.
- SOPs reviewed for the processing steps relevant to your tissue type.
- Facility environmental controls and monitoring program reviewed.
- Equipment maintenance and calibration records reviewed.
- Process validation data reviewed for the cryopreservation protocol.
- Deviation reporting policy reviewed.
- Record retention confirmed at the 10-year minimum.
- Reference calls completed with other physician clients.
- Agreement reviewed by healthcare counsel before execution.
Frequently Asked Questions
Does CGTP apply to 361 tissues that do not need FDA approval?
Yes. CGTP under Subpart D of 21 CFR Part 1271 applies to all registered HCT/P establishments, including those manufacturing 361 products. The lack of a pre-market approval step does not exempt a facility from the quality standard.
How long must HCT/P records be retained?
At least 10 years after creation, and for records pertaining to a particular HCT/P, at least 10 years after its administration, distribution, disposition, or expiration, whichever is latest.
If my lab partner violates CGTP, is that only the lab’s problem?
No. The physician who uses the tissue is in the distribution chain and can face regulatory, civil, and potentially criminal exposure if a CGTP failure leads to patient harm. Reviewing the partner’s compliance is part of the physician’s due diligence.
Key Takeaways
CGTP is the federal quality floor for tissue, and the physician’s mistake to avoid is treating it as the lab’s problem alone. Subpart D of Part 1271 sets requirements across personnel, procedures, facilities, environmental monitoring, equipment, supplies, processing, labeling, storage, records, and deviation reporting, with a 10-year record-retention minimum, and it binds 361 establishments just as it binds others. Because the physician who administers the tissue sits in the distribution chain, a lab partner’s CGTP failure becomes the physician’s exposure, which is why each requirement above should be turned into a written question and a documented answer before any agreement is signed. The Florida-specific filtration claim that circulates is best handled by reading CGTP and the enrolled statute rather than a superseded draft. And as always, banking is a preservation decision separate from therapeutic use, carrying no guarantee of future benefit.
Save My Fat operates as a tissue preservation service, not a medical practice or treatment provider. Stem cell and regenerative medicine regulations vary by state, including specific informed-consent and disclosure requirements in Florida, Utah, and Nevada governing tissue and stem cell services. Banking adipose tissue does not connect patients to any treatment pathway, and any future use depends on FDA regulatory status, physician guidance, and the availability of approved or investigational pathways at that time.
Physicians vetting a tissue processing or storage partner can contact Save My Fat to discuss how laboratory processing works. Service and processing details are available at https://savemyfat.com/pricing/.
Save My Fat partners with L2 Bio for laboratory processing and storage.
This article is for educational purposes only and does not constitute medical or legal advice. Legal and medical review including neurology and neurosurgery input is required before publication. Please consult your neurologist or neurosurgeon before making any decisions about neurologic treatment or research participation.
